Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.59 |
| ▸ | FNTB | P49356 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.52 |
| ▸ | CDC25A | P30304 | 6/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CDC45 | O75419 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24104660 | 0.91 | FNTA (0.66) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL17817290 | 0.91 | FNTA (0.66) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL13153840 | 0.87 | FNTA (0.59) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL24104661 | 0.85 | FNTA (0.57) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL17817648 | 0.85 | FNTA (0.57) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL29358993 | 0.83 | FNTA (0.61) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL8417553 | 0.82 | FNTA (0.66) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL17817291 | 0.80 | FNTA (0.64) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL17817641 | 0.80 | FNTA (0.56) | FNTAFNTBCYP2D6CYP2C19INPP5D | |
| SCHEMBL25382848 | 0.79 | CYP2D6 (0.56) | FNTAFNTBCYP2D6CYP2C19INPP5D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | FNTA 2403/4885FNTB 2679/4885CYP2D6 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.